Open AccessRapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study
Author(s) -
Jamshid Ahmadi,
Ebrahim Moghimi Sarani,
Mina Sefidfard Jahromi
Publication year - 2020
Publication title -
tzu-chi medical journal/cí-jì yīxué
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.343
H-Index - 15
eISSN - 2223-8956
pISSN - 1016-3190
DOI - 10.4103/tcmj.tcmj_220_18
Subject(s) - medicine , buprenorphine , craving , placebo , suicidal ideation , anesthesia , opioid , randomized controlled trial , double blind , psychiatry , emergency medicine , poison control , surgery , addiction , suicide prevention , alternative medicine , receptor , pathology
Opioid use disorder is a prevalent addiction problem that can be treated with buprenorphine, but dependence, diversion, and abuse of buprenorphine occur. Although including naloxone reduces these problems, the combination formulation is not available worldwide. The administration of the medication under supervision may also be useful in decreasing unintended uses of the medication. The objective is to assess the influence of a single, physician-administered dose of buprenorphine on withdrawal craving and suicidal ideation in opioid-dependent patients over a period of 4 days of abstinence from opioids.